MRL Ventures Fund and Roche Fund have taken part in the intracellular drug developer's series A, which is commercialising research by Prof Dehua Pei at OSU.

Entrada Therapeutics, a US-based drug delivery platform developer based on reseach at Ohio State University (OSU), raised $59m in a series A round co-led by VC firm 5AM Ventures and healthcare investment firm MPM Capital on Tuesday.
Pharmaceutical firms Merck & Co and Roche participated in the round through respective corporate venturing units Roche Fund and MRL Ventures Fund, while Agent Capital also contributed funding.
Founded in 2016, Entrada has developed intracellular technology intended to help medicines access both small…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?